Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...
Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...
Jaypirca is approved for the treatment of adults with relapsed or refractory CLL/SLL who were previously treated with a ...
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult ...
Clinical Trials Arena on MSN
Eli Lilly reports Phase III trial results of Jaypirca for CLL/SLL
The results demonstrated that pirtobrutinib met its primary endpoint of non-inferiority on ORR against ibrutinib.
Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
A single dose of a four-drug combination therapy for uncomplicated malaria was just as effective as the multi-day standard of care treatment, according to data presented at the American Society of ...
Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback